# REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

> **NCT04526106** · PHASE1,PHASE2 · COMPLETED · sponsor: **Elevar Therapeutics** · enrollment: 490 (actual)

## Conditions studied

- FGFR2 Amplification
- FGFR2 Gene Mutation
- FGFR2 Gene Fusion/Rearrangement
- FGFR2 Gene Translocation
- FGFR2 Gene Activation
- Intrahepatic Cholangiocarcinoma
- Cholangiocarcinoma
- Other Solid Tumors, Adult

## Interventions

- **DRUG:** RLY-4008

## Key facts

- **NCT ID:** NCT04526106
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-02
- **Primary completion:** 2025-09-05
- **Final completion:** 2025-09-05
- **Target enrollment:** 490 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526106, "REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04526106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*